© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 19, 1437-1439,
October 3, 2001
© 2001 Oxford University Press
EDITORIAL |
Future for Ovarian Cancer Screening: Novel Markers From Emerging Technologies of Transcriptional Profiling and Proteomics
Affiliations of authors: G. B. Mills, R. C. Bast, Jr., The University of Texas M. D. Anderson Cancer Research Center, Houston; S. Srivastava, Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD.
Correspondence to: Sudhir Srivastava, Ph.D., MPH, National Institutes of Health, 6130 Executive Blvd., Suite 3142, Rockville, MD 20851 (e-mail: ss1a@nih.gov).
The completion of the human genome project and the burgeoning use of genomic, transcriptional profiling, and proteomic technologies to investigate DNA, RNA, and protein levels in tumors, serum, plasma, and urine offer the exciting potential of identifying novel and effective cancer-specific screening markers. If the markers are secreted or released from tumor cells and migrate to serum, plasma, urine, or other accessible sites, they may be useful as screening markers either alone or in combination with currently identified tumor markers or screening approaches. Thus, these technologies potentially provide for a rapid advance in the identification of novel tumor markers comparable to that initiated by the introduction of monoclonal antibody technology.
In this issue of the Journal, Mok et al. (1), using transcriptional profiling of ovarian cancer cell lines, found that messenger RNA (mRNA) levels of prostasin (a serine protease, previously identified in prostatic secretions), osteopontin (a secreted
NOTES
REFERENCES
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Simon, S. Zhuo, L. Corral, E. P. Diamandis, M. J. Sarno, R. L. Wolfert, and N. W. Kim B7-H4 Is a Novel Membrane-Bound Protein and a Candidate Serum and Tissue Biomarker for Ovarian Cancer Cancer Res., February 1, 2006; 66(3): 1570 - 1575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Masciari and J. E. Garber Quality or Quantity in the Management of Hereditary Ovarian Cancer Risk: Is It Really a Trade-Off? J. Clin. Oncol., October 1, 2005; 23(28): 6817 - 6819. [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Kozak, M. W. Amneus, S. M. Pusey, F. Su, M. N. Luong, S. A. Luong, S. T. Reddy, and R. Farias-Eisner Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis PNAS, October 14, 2003; 100(21): 12343 - 12348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ye, D. W. Cramer, S. J. Skates, S. P. Gygi, V. Pratomo, L. Fu, N. K. Horick, L. J. Licklider, J. O. Schorge, R. S. Berkowitz, et al. Haptoglobin-{alpha} Subunit As Potential Serum Biomarker in Ovarian Cancer: Identification and Characterization Using Proteomic Profiling and Mass Spectrometry Clin. Cancer Res., August 1, 2003; 9(8): 2904 - 2911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kishi, L. Grass, A. Soosaipillai, A. Scorilas, N. Harbeck, B. Schmalfeldt, J. Dorn, M. Mysliwiec, M. Schmitt, and E. P. Diamandis Human Kallikrein 8, a Novel Biomarker for Ovarian Carcinoma Cancer Res., June 1, 2003; 63(11): 2771 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis, A. Scorilas, S. Fracchioli, M. van Gramberen, H. de Bruijn, A. Henrik, A. Soosaipillai, L. Grass, G. M. Yousef, U.-H. Stenman, et al. Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma J. Clin. Oncol., March 15, 2003; 21(6): 1035 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-Y. Luo, D. Katsaros, A. Scorilas, S. Fracchioli, R. Bellino, M. van Gramberen, H. de Bruijn, A. Henrik, U.-H. Stenman, M. Massobrio, et al. The Serum Concentration of Human Kallikrein 10 Represents a Novel Biomarker for Ovarian Cancer Diagnosis and Prognosis Cancer Res., February 15, 2003; 63(4): 807 - 811. [Abstract] [Full Text] [PDF]
|
|